Open Innovation Drug Discovery

News and Announcements

+

The Lilly Phenotypic Assays Data for NCATS Collection Now in Public Domain

The Lilly Open Innovation Drug Discovery (OIDD) Program and The National Center for Advancing Translational Sciences (NCATS) released the results obtained from the characterization of 2460 clinical phase approved drugs in five Phenotypic OIDD modules via The Open innovation Phenotypic Drug Discovery Resource and PubChem.

The NCATS pharmaceutical collection was profiled in the Open Innovation Drug Discovery phenotypic assay panel, a unique and well vetted phenotypic assessment of small molecules in five models of disease including Wnt potentiation (osteoporosis model), insulin and GLP-1 secretion (diabetes models), KRAS-Wnt synthetic lethality, and angiogenesis (cancer models). Full discussion of this work has also been published in a recent PLOS One article.

Additional screens on these compounds may be released on this site when available.

OIDD Undergraduate Work Study Program

The Lilly OIDD program provides an undergraduate program for qualified academic participants. Read more about the Undergraduate Work Study Program in the Guidelines document.

UTSA Professor Wins Outstanding OIDD Collaborator Award

For the past five years, Frantz’s graduate and post-doctoral students have synthesized nearly 1,500 new chemical compounds and submitted them to the Lilly OIDD program. Under a collaborative agreement, Lilly has run additional experiments to further profile these compounds. His lab’s participation earned Professor Doug Frantz Lilly’s Outstanding Open Innovation Drug Discovery Collaborator Award, as announced by UTSA sources. document.

New Synthesis Capabilities Launched at OIDD

The Lilly OIDD team is now offering participating investigators the opportunity to synthesize compounds remotely in Lilly's Automated Synthesis Laboratory (ASL). The ASL provides synthetic chemists with an opportunity to improve yields, explore novel synthetic approaches, and improve efficiency of synthetic transformations.

Neglected and Tropical Disease Screening Expanded to Include Malaria

OIDD recently expanded its involvement in neglected and tropical disease research working in conjuction with Medicines for Malaria Venture.

OIDD Team at Conferences

To schedule a meeting with an OIDD representative at any of the conferences listed below, please email openinnovation@lilly.com.

  • AUTM 2017 Annual Meeting–Hollywood, Florida
    March 12–15, 2017
  • 2017 BIO Europe Spring Convention–Barcelona, Spain
    March 20–22, 2017
  • 253rd American Chemical Society National Meeting–San Francisco, California
    April 2–6, 2017
  • 2017 BioHealth Capital Region Forum– Gaithersburg, Maryland
    April 19–20, 2017
  • 2017 BIO International Convention–San Diego, California
    June 19–22, 2017
  • AUTM 2017 Central Region Meeting–Chicago, Illinois
    July 10–12, 2017